Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL... see more

Recent & Breaking News (TSX:MDNA)

Medicenna Announces Trading on the OTCQX Best Market in the United States

Canada NewsWire October 18, 2017

Medicenna Presents Clinical Data on Initial Experience from Ongoing Phase 2b Study of MDNA55

Canada NewsWire October 10, 2017

Medicenna Updates On-Going Phase 2b Clinical Trial Protocol for Recurrent Glioblastoma

Canada NewsWire September 28, 2017

Medicenna Announces Late Breaking Oral Presentation at the 2017 Congress of Neurological Surgeons (CNS) Annual Meeting

Canada NewsWire September 25, 2017

Medicenna Appoints Dr. William Li to Board of Directors

Canada NewsWire September 21, 2017

Medicenna to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

PR Newswire September 6, 2017

Technical Research on Chemicals Equities -- Air Products and Chemicals, Eastman Chemical, Praxair, and Tronox

PR Newswire August 16, 2017

Medicenna Reports First Quarter Fiscal 2018 Financial Results

Canada NewsWire August 9, 2017

Medicenna Announces Graduation to the TSX

Canada NewsWire August 1, 2017

Medicenna Bolsters Management Team

Canada NewsWire July 17, 2017

Medicenna Announces March 31, 2017 Year End Results

Canada NewsWire June 16, 2017

Medicenna's Immunotherapy Phase 2b Trial Underway Using Brainlab Drug Delivery Technology

Canada NewsWire June 8, 2017

Medicenna Therapeutics Corp. Opens the Market

Canada NewsWire May 25, 2017

Medicenna Therapeutics Opens the Market

Canada NewsWire May 25, 2017

Medicenna Strengthens Patent Portfolio for its Lead Clinical Candidate, MDNA55

Canada NewsWire April 27, 2017

Medicenna to Present at Bloom Burton & Co. Healthcare Investor Conference 2017

Canada NewsWire April 20, 2017

Medicenna Treats First Patient in Phase 2b Recurrent Glioblastoma Trial

Canada NewsWire April 13, 2017

Medicenna BioPharma Announces Strategic Collaboration with MD Anderson Cancer Center to Advance Next Generation Empowered Cytokines™

Canada NewsWire March 16, 2017

Medicenna shares resume trading under the symbol "MDNA"

Canada NewsWire March 8, 2017

IIROC Trading Resumption - AFCC; BTRU; LMC; MDNA; PGZ

Canada NewsWire March 7, 2017